Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Five Patent Applications Related to RNAi: May 10, 2007

Premium
Title: Devices and Processes for Distribution of Genetic Material to Mammalian Limb
 
Numbers: 7,214,369
 
Filed: May 5, 2003
 
Lead Inventor: Jon Wolff, Mirus Bio
 
The patent, its abstract states, covers “a process … for the delivery of a therapeutic polynucleotide to limb muscle tissue suffering from or potentially suffering from ischemia. The polynucleotide is inserted into a mammalian limb vessel such as an artery. Delivery efficiency and distribution is enhanced by combining injection of a solution containing the polynucleotide with the use of an externally applied cuff.”
 

 
Title: siRNA Targeting Carbonic Anhydrase II
 
Numbers: 20070099862
 
Filed: Dec. 7, 2006
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
According to the patent application’s abstract, “efficient sequence-specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.”
 

 
Title: Compositions and Methods for Inhibiting Expression of Huntingtin Gene
 
Numbers: 20070099860
 
Filed: Oct. 27, 2006
 
Lead Inventor: Dinah Wen-Yee Sah, Alnylam Pharmaceuticals
 
“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the huntingtin gene, comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene,” the patent application’s abstract states. “The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.”
 

 
Title: RNA Interference Method of Inhibition of Influenza Virus Gene Expression Using Short Interfering Nucleic Acid
 
Numbers: 20070099858
 
Filed: Oct. 3, 2005
 
Lead Inventor: Vasant Jadhav, Sirna Therapeutics (Merck)
 
“This invention relates to compounds, compositions, and methods useful for modulating influenza virus gene expression using short interfering nucleic acid molecules,” the patent application’s abstract states. “In particular, the instant invention features small nucleic acid molecules … and methods used to modulate the expression of influenza virus genes, such as viral and host genes associated with the maintenance or development of influenza virus infection and related diseases and conditions in a subject or organism.”
 

 
Title: Methods and Means for Inhibiting Fever
 
Numbers: 20070099857
 
Filed: Sept. 1, 2004 PCT Filed: Sept. 1, 2004
 
Lead Inventor: Andres Blomqvist, Karolinska Institutet
 
“Microsomal prostaglandin E synthase-1 catalyses the terminal step in the synthesis of prostaglandin E2 in the brain,” the patent application’s abstract states. “In the absence of mPGES-1, animals do not develop immune-induced fever, but retain a normal pyretic response to central administration of PGE2. Inhibitors of PGES-1 can be used for treating fever and other PGE2-dependent reactions. Assays for inhibitors of mPGES-1 are provided.”
 
The application specifically claims a double-stranded RNA “corresponding to the sequence of a gene encoding mPGES-1 or a fragment thereof” used as an inhibitor of “a gene encoding microsomal PGE synthase-1 activity.”
 

 
Title: Novel Oligonucleotide Compositions and Probe Sequences Useful for Detection and Analysis of microRNAs and Their Target mRNAs
 
Numbers: 20070099196
 
Filed: Dec. 29, 2005
 
Lead Inventor: Sakari Kauppinen, University of Copenhagen (Santaris Pharma)
 
According to its abstract, the patent application relates to “ribonucleic acids and oligonucleotide probes useful for detection and analysis of microRNAs and their target mRNAs, as well as small interfering RNAs.”